On the need for outcome trials in preventive pharmacology. Lessons from the recent experience with adverse drug reactions.
Stern
M P
MP
Department of Medicine, University of Texas Health Science Center, San Antonio 78284, USA. stern@uthscsa.edu
D002839:Chromans / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D013844:Thiazoles / Q000009:adverse effects*; D045162:Thiazolidinediones; D016896:Treatment Outcome; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone